nanovibronix.com - רווח החברה לפני מסים, ריבית ופחת NAOV

NanoVibronix, Inc. (NAOV) develops patented portable devices to combat catheter-associated infections, operating within a stable geopolitical environment free of trade restrictions. The change in EBITDA captures daily operating profit, while 0.00 reflects the current value of the metric. Growth is driven by the implementation of UroShield systems and the expansion of insurance reimbursements in the US for non-invasive pain management.

To filter for fundamentally resilient assets, investors utilize cash flow analysis before debt and tax obligations, which allows for an assessment of a business's actual ability to generate capital. This actual EBITDA confirms the financial stability of NanoVibronix, Inc., where revenue from the sale of ultrasonic equipment fully covers current expenses, eliminating the risk of liquidity shortages.